source
- BridgeBio eyes first FDA approval for limb-girdle muscular dystrophy therapyBridgeBio Pharma is preparing for a potential launch of its experimental drug BBP-418 aimed at treating limb-girdle muscular dystrophy type 2I/R9, pending FDA decision. The agency has set a review…
- Midterm voters weigh health-care costs as urgent-care visits billed like ERsThe upcoming midterm elections will see tens of millions of voters consider health‑care affordability, especially those whose coverage comes through their employers. The article points out that ri…